First-Quarter 2012 Business Review

24 April, 2012

bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2012.

Sales up 9.3% at constant exchange rates

  • Of which 3.1% organic growth, in line with objectives
  • Strong momentum* in China (up 47%) and India (up 31%)
  • Solid performance* in industrial applications (up 11.6%)

Significant operational advances

2012 sales growth objective confirmed

Net sales for the period amounted to €363 million, versus €328 million in first-quarter 2011, representing an increase of 9.3% at constant exchange rates. Organic growth amounted to 3.1%, at constant exchange rates and comparable business base**.

* At constant exchange rates and comparable business base

** Excluding the acquisition of AES Laboratoire and ARGENE, the divestiture of Dima Diagnostika and the discontinuation of culture media business for routine clinical tests in North America

Download the Full Report:

Download
Pioneering Diagnostics